United States: Healthcare

Welcome to Wiley's update on recent developments and what's next in consumer protection at the Federal Trade Commission (FTC), Consumer Financial Protection Bureau (CFPB), and the state level.

The first week of October 2025 marked a significant shift in U.S. drug pricing policy as the Trump administration unveiled a series of sweeping actions to deliver on his promise to lower drug prices

The U.S. Food and Drug Administration (FDA) issued new draft guidance on Sept. 20, 2025, surrounding expedited programs for regenerative medicine therapies for serious conditions.

Funding for much of the federal government lapsed on October 1 with the start of a new fiscal year. Government funding is supposed to be enacted through passage of 12 annual appropriations bills or a stopgap measure...

In the first part of this special guest episode of "The Trial Lawyer's Handbook" podcast series, litigation attorney Dan Small is joined by Partner Eric Alexander, who leads the firm's Product Liability...

On Tuesday, September 30, as part of the administration's announcement of a Most Favored Nation (MFN) pricing agreement with Pfizer, the White House stated that tariffs on other branded drug manufacturers would be paused while MFN negotiations with such manufacturers continue, in addition to announcing a specific three-year grace period for tariffs on Pfizer's products

Childcare check-in systems are recommended for faith-based organizations that serve families. Whether it's Sunday school, daycare, or youth programs, these systems help ensure children...

Ambulatory surgical centers (ASCs) continue to face a rapidly evolving regulatory landscape at both the state and federal levels.

In September 2025, the California Court of Appeal, Third Appellate District, issued a judgment confirming that strict liability does not apply to the security requirements under California's medical information breach notification law.